Guru Ownership Trend
Guru Analysis for CRISPR Therapeutics AG (CRSP)
CRISPR Therapeutics AG (CRSP), a key player in the Healthcare sector, continues to attract institutional attention.
As of Q1 2026, a total of 4 Super Investors (Gurus) hold positions in the company, with a combined stake valued at approximately $567.18 M.
Top institutional holders include Catherine Wood and Paul Tudor Jones.
Institutional sentiment is currently Bullish. This is evidenced by a $37.89 M net inflow during the quarter.
Recent activity highlights Paul Tudor Jones who increased their stake by 10.0%. Conversely, Murray Stahl reduced exposure by 4.3%.
Key Holders
Top 5 by Value
Top 5 by Conviction
Recent Activity Breakdown (Q1 2026)
Guru Consensus (Q1 2026)
FAQs for CRISPR Therapeutics AG (CRSP)
Major holders include Catherine Wood ($538.19 M), Paul Tudor Jones ($2.07 M), Cliff Asness ($1.06 M). According to the latest reported data, 4 tracked investment managers collectively hold approximately 11.39 M shares.
According to the latest 13F reporting period, sentiment appears Bullish (Net Buying). There was a net inflow of $37.89 M, with 3 managers increasing positions and 1 managers reducing holdings.
During the most recent reporting period, 1 managers trimmed their positions, while 0 fully exited CRSP. The total reported sell value was $21,073.52.
Yes, 0 managers opened new positions in CRSP, and 3 increased their existing holdings. The total reported buy value was $37.91 M.